Core Insights - Heng Rui Medicine has reached an agreement with GSK to grant global exclusive rights for the HRS-9821 project and up to 11 additional projects, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - GSK will pay Heng Rui a $500 million upfront payment, and both companies will jointly develop up to 12 innovative drugs [1] - If all projects are exercised and all milestones are achieved, Heng Rui could receive potential milestone payments totaling approximately $12 billion based on successful development, registration, and sales [1] - HRS-9821 is Heng Rui's first respiratory pipeline project introduced by an international giant, with a total potential transaction value of $12.5 billion, setting a record for Chinese innovative drugs going abroad and reaffirming the potential of the PDE3/4 target [1] - The report maintains a "strong buy" rating for Heng Rui Medicine [1]

Market Overview - The A-share market experienced a divergence with the Shanghai Composite Index stabilizing above 3600 points, but individual stocks showed weakness, indicating underlying complexities in market dynamics [1] - The upcoming Federal Reserve meeting is anticipated to have significant implications for global capital markets, with a high probability of maintaining interest rates unchanged [3] Federal Reserve Insights - The Federal Reserve's meeting is expected to reveal potential dissenting votes advocating for a 25 basis point rate cut, which would be a rare occurrence since 1993 [3] - Market participants are closely monitoring Chairman Powell's statements for any dovish signals regarding a potential rate cut in September, particularly concerning economic risks and inflation [3] External Market Influences - U.S. stock indices experienced a pullback, with the Dow Jones down 0.46%, while European markets, particularly the German DAX, rose by 1.03% due to easing trade tensions [3] - The extension of a 24% reciprocal tariff suspension between China and the U.S. and the easing of high-end chip export restrictions are seen as positive developments for the semiconductor and AI sectors [3] A-share Market Dynamics - Northbound capital saw a net inflow of 1.82 billion yuan, reversing six consecutive days of net selling, with significant investments in the semiconductor and pharmaceutical sectors, particularly in innovative drug companies [4] - There is a noticeable divergence in main capital flows, with some sectors like real estate and biopharmaceuticals seeing increased investment, while automotive and machinery sectors faced sell-offs due to disappointing consumer recovery [4] Technical Analysis - The Shanghai Composite Index's stability above 3600 points is accompanied by a lack of strong buying momentum, as indicated by a low trading volume of 73.5 billion yuan in the first half hour [4] - The ChiNext Index showed a strong performance, breaking through 2400 points, driven by gains in the pharmaceutical and technology sectors [4] Policy Developments - A significant press conference is scheduled to announce new childcare subsidies and fertility support measures, which could provide a short-term boost to the maternal and educational consumption sectors [4] - Long-term investors are encouraged to focus on sectors with sustained policy benefits, such as innovative drugs and domestic AI computing capabilities [4] Investment Strategies - Short-term market fluctuations are expected to continue around the 3600-point mark, with three key areas of focus: semiconductor components, innovative drugs, and military industry due to rising expectations from the upcoming Zhuhai Airshow [5] - Long-term investors are advised to remain focused on the overarching themes of trade easing and corporate profit growth, regardless of short-term market volatility [5]

为持续向投资者普及ETF基础知识，招商证券携手十大基金公司，联合全景网共同举办2025年招商证 券"招财杯"ETF实盘大赛系列直播，旨在帮助投资者提升资产配置与风险管理能力，促进ETF市场的健 康发展。 2025年7月24日，"招财杯"ETF实盘大赛系列直播邀请到了银华基金指数投资分析师辛迪，一起探讨 《创新药板块崛起，后市还有哪些机会？》。 辛迪表示，经过近几年的快速发展，我国已成为全球创新药领域的重要力量，尤其在研发管线规模、靶 点覆盖及国际化合作方面表现突出，而众多创新药企也将开始进入成果兑现阶段，中国创新药行业或正 在进入厚积薄发的"收获期"。 "总体而言，政策、资本、产业因素共振，中国创新药行业长期成长逻辑坚实。"辛迪进一步表示，"我 认为创新药估值仍有非常充足的上扬空间。" 部分企业业绩超预期，创新药或步入"收获期" 辛迪：从基本面来看，我们认为创新药仍是当前医药板块中产业趋势最为明确且具备未来成长空间的子 行业，全年维度创新药作为医药板块的投资主线不会变化，创新药大时代已然到来。此外，7月中报业 绩预告/快报陆续披露，GLP-1景气赛道、困境反转的原料药等表现亮眼，从半年报情况看，部分企业 H1 ...

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has entered into an agreement with GlaxoSmithKline (GSK) to grant global exclusive rights for the HRS-9821 project and up to 11 additional projects, excluding certain regions in China, for a payment of $500 million upfront, with potential milestone payments totaling approximately $12 billion [2][3] Group 1: Agreement Details - The agreement includes HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD), which shows strong PDE3 and PDE4 inhibition and potential for dry powder inhalation formulation [3] - Hengrui retains all rights for HRS-9821 in mainland China, Hong Kong, Macau, and Taiwan, while granting GSK global exclusive rights for other regions [3] - The collaboration also involves 11 innovative drug projects in non-clinical research stages, covering oncology, respiratory, autoimmune, and inflammatory treatment areas [3] Group 2: Market Impact and Strategic Benefits - The partnership is expected to broaden the overseas market for HRS-9821 and other innovative products, enhancing Hengrui's brand and overseas performance [3] - Hengrui can leverage GSK's global commercialization network to overcome market entry barriers and shorten the development cycle for innovative drugs [4] - The collaboration allows Hengrui to maintain control over core market rights while sharing the financial burden of high R&D costs with GSK, creating a synergistic market strategy [4] Group 3: Industry Recognition and Future Outlook - The collaboration model reflects international recognition of China's innovative drug development capabilities and provides a reference for local pharmaceutical companies exploring internationalization [5] - The long development cycle of pharmaceuticals necessitates a long-term validation of the collaboration's effectiveness, urging investors to consider the relationship between short-term market reactions and long-term value realization [5]

Core Viewpoint - The innovative drug sector is experiencing a significant surge driven by strong earnings, overseas orders, and favorable policies [2][3][6]. Group 1: Market Performance - On July 29, both A-shares and Hong Kong stocks in the innovative drug sector saw substantial gains, with multiple stocks rising over 10% [2][4][5]. - Notable performers included Yaoshan Technology, Tigermed, and WuXi Biologics, all of which saw significant increases [4]. Group 2: Key Drivers - **Earnings Growth**: WuXi Biologics reported a revenue of 20.799 billion yuan for the first half of 2025, a year-on-year increase of 20.64%, and a net profit of 8.561 billion yuan, up 101.92% year-on-year. The company raised its full-year revenue forecast to between 42.5 billion and 43.5 billion yuan [6]. - **International Expansion**: Heng Rui Medicine announced a partnership with GlaxoSmithKline (GSK), which includes a $500 million upfront payment and potential milestone payments totaling around $12 billion for 12 projects in respiratory diseases, oncology, and autoimmune diseases [6]. - **Policy Support**: The National Healthcare Security Administration held discussions to support the high-quality development of innovative drugs, emphasizing the use of healthcare data to support drug research and development [7][8]. Group 3: Future Outlook - Analysts suggest that the innovative drug sector is in a phase of dual support from policy and fundamentals, indicating a potential for value re-evaluation [10]. - The current valuation of the innovative drug sector remains attractive compared to major pharmaceutical companies in the U.S., with both domestic and foreign investments expected to increase [11][12]. - The sector is seen as a key investment theme for the year, with a focus on high-quality companies and emerging sub-sectors such as CRO&CDMO and specialty raw materials [12][13].

Core Insights - The innovative drug sector in both Hong Kong and A-shares continues to show strong momentum, with notable gains in stocks such as WuXi AppTec and others [1] - WuXi AppTec reported a significant increase in revenue and net profit for the first half of the year, indicating robust financial performance [1] - The market is actively trading with ETFs related to the biotech sector reaching new highs, reflecting investor confidence [1] Group 1: Market Performance - The Hong Kong stock market saw WuXi AppTec leading with over a 10% increase, followed by other companies like Sihuan Pharmaceutical and Tigermed [1] - In the A-share market, Jiuzhou Pharmaceutical hit the daily limit, while Tigermed rose over 10% [1] - The Hang Seng Biotechnology ETF (159615) increased nearly 4%, reaching a record high since its launch, while the Southern Innovative Drug ETF (159858) rose over 3% [1] Group 2: Company Financials - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of the year, a year-on-year increase of 20.64% [1] - The net profit attributable to shareholders was 8.56 billion yuan, showing a remarkable growth of 101.92% [1] - In Q2, the company achieved a revenue of 11.145 billion yuan, marking the first time it surpassed the 10 billion yuan mark in that quarter, with a net profit of 4.889 billion yuan, a historical high for the same period [1] Group 3: Industry Outlook - Aijian Securities expressed optimism about the ongoing heat in the innovative drug sector and the structural market trends, particularly regarding the international expansion of Chinese innovative drugs [1] - The focus is on key areas such as Antibody-Drug Conjugates (ADC) and bispecific antibodies, with an emphasis on tracking industry catalysts and business development progress [1]

Group 1 - The core viewpoint of the articles highlights the strong performance of the Hong Kong stock market, particularly in the innovative pharmaceutical sector, with significant gains in related stocks and ETFs [1][2] - The Hong Kong Innovation Drug 50 ETF (513780) has seen a remarkable increase of 100% year-to-date, indicating robust investor interest and confidence in the sector [1] - WuXi AppTec reported a substantial revenue of 20.64% growth year-on-year, reaching 20.799 billion yuan, and a net profit increase of 101.92%, amounting to 8.561 billion yuan, marking a significant milestone of over 10 billion yuan in quarterly revenue for the first time [1] Group 2 - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for 69.65% of the index, including high-quality A-share companies like Innovent Biologics and Stone Pharmaceutical [2] - The innovative drug sector in China is at a new historical starting point, with domestic companies enhancing their competitiveness and expanding overseas, supported by favorable policies [2] - The industry is experiencing rapid revenue growth and is transitioning into a new profit-driven cycle, presenting investment opportunities in high-quality, undervalued companies within the sector [1][2]

Core Viewpoint - Heng Rui Medicine has made a significant announcement regarding its collaboration with GlaxoSmithKline (GSK), involving the licensing of global exclusive rights for the HRS-9821 project and up to 11 additional projects, marking a record for the company's innovative drug exports [2][3][4]. Group 1: Financial Details - The initial payment from GSK to Heng Rui is $500 million, with potential milestone payments amounting to approximately $12 billion, setting a new record for Heng Rui's innovative drug exports [2][4]. - Since the beginning of 2024, Heng Rui's total contract value from innovative drug exports is expected to exceed $20 billion [6]. - In Q1 2025, Heng Rui reported a net profit of 1.874 billion yuan, representing a year-on-year increase of 36.90% [9]. Group 2: Research and Development - Heng Rui's R&D investment for 2024 is 8.228 billion yuan, accounting for 29.40% of its operating revenue, with total R&D investment over the past decade reaching 42.267 billion yuan [2][7]. - The company has a robust pipeline with over 90 innovative products in clinical development and approximately 400 clinical trials ongoing domestically and internationally [7][8]. Group 3: Market Impact - Following the announcement of the record deal, Heng Rui's stock price surged, bringing its market capitalization back to 411.77 billion yuan [10]. - In 2024, Heng Rui's innovative drug sales revenue reached 13.892 billion yuan, a year-on-year increase of 30.60% [8].

Core Viewpoint - Heng Rui Medicine has entered into an agreement with GSK to grant global exclusive rights (excluding mainland China, Hong Kong, Macau, and Taiwan) for the HRS-9821 project, with an upfront payment of $500 million and potential total payments of approximately $12 billion [1][2] Group 1: Financial Aspects - The agreement includes an upfront payment of $500 million for the PDE3/4 inhibitor HRS-9821, with potential milestone payments totaling around $12 billion if all projects are successfully developed and commercialized [2] - The domestic innovative drug sector has seen significant transactions, with some reaching tens of billions to over a hundred billion dollars [2] - In 2024, the total amount of overseas licensing transactions for innovative drugs in China is expected to grow by 26% year-on-year, with upfront payments exceeding $2.5 billion and total transaction amounts surpassing $50 billion [4][5] Group 2: Market Trends - The innovative drug sector in China is transitioning from generic drugs to innovative drugs, with a notable increase in the number of original drug candidates entering clinical trials [4] - By 2024, China is expected to have 120 original drug candidates in development, accounting for 24% of the global total, second only to the United States [4] - The approval efficiency for innovative drugs is being enhanced, with a goal to complete clinical trial reviews within 30 working days for qualifying applications [6] Group 3: Policy Support - Recent government policies have aimed to optimize drug procurement and support the long-term development of innovative drugs, including the introduction of commercial health insurance for innovative drugs [5] - The National Medical Insurance Bureau has proposed a "commercial insurance first, then medical insurance" model for innovative drugs not covered by basic medical insurance, which could facilitate their commercialization [5] - Continuous policy support is crucial for the innovative drug industry, which faces challenges due to long development cycles and high costs [5]

Market Performance - The market experienced a rebound on July 28, with the ChiNext Index leading the gains, closing up by 0.96% [1] - The Shanghai Composite Index rose by 0.12%, and the Shenzhen Component Index increased by 0.44% [1] Sector Performance - The computing hardware sector saw a significant surge, while innovative drug concept stocks maintained strong performance [1] - Active performance was noted in military and commercial aerospace concept stocks [1] - Conversely, cyclical stocks such as steel and coal experienced collective adjustments [1] ETF Performance - All ETFs that rose were related to innovative drugs, with the East Money Fund's Innovative Drug ETF (159622) leading the market with a 4.1% increase [3] - Other notable ETFs in the innovative drug sector also saw gains, with the Hong Kong Innovative Drug 50 ETF (513780) up by 4.04% and the Hong Kong Innovative Drug ETF (513120) up by 4.01% [3] Policy Updates - On July 24, the National Medical Insurance Administration announced the initiation of the 11th batch of centralized procurement, optimizing specific rules regarding the selection process [2] - The new rules will no longer simply use the lowest bid as a reference point, and companies with the lowest bids must publicly justify their pricing [2] Industry Insights - According to a report by Industrial Securities, the AACR and ASCO meetings this year showcased numerous domestic innovative drugs exceeding expectations, with anticipation for data releases from upcoming industry conferences [4] - There has been ongoing progress in foreign licensing transactions for innovative drugs, with expectations for more high-quality domestic products to explore international opportunities [4]